Optimization and proficiency testing of a pseudovirus-based assay for detection of HIV-1 neutralizing antibody in China

Journal of Virological Methods

Volumn 185, Issue 2, 2012, Pages 267-275

  Nie, Jianhui ^a,f   Wang, Wenbo ^a   Wen, Zhiheng ^a   Song, Aijing ^a   Hong, Kunxue ^b   Lu, Shan ^c   Zhong, Ping ^d   Xu, Jianqing ^e   Kong, Wei ^f   Li, Jingyun ^g   Shang, Hong ^h   Ling, Hong ⁱ   Ruan, Li ^j   Wang, Youchun ^a  

^a NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d Shanghai CDC ^*  (China)

^e FUDAN UNIVERSITY   (China)

^f JILIN UNIVERSITY   (China)

^g BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^h CHINA MEDICAL UNIVERSITY   (China)

ⁱ HARBIN MEDICAL UNIVERSITY   (China)

^j Institute for Viral Disease Control and Prevention   (China)

more..

Author keywords

HIV; Neutralizing antibody assay; Proficiency test; Pseudovirus; TZM bl

Indexed keywords

ANTICOAGULANT AGENT; DIETHYLAMINOETHYLDEXTRAN; HUMAN IMMUNODEFICIENCY VIRUS 1 ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ANTIBODY DETECTION; ARTICLE; CELL COUNT; CHINA; CLINICAL ASSESSMENT TOOL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOASSAY; INOCULATION; LABORATORY TEST; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PSEUDOVIRUS BASED ASSAY; RELATIVE LIGHT UNIT; SERUM; VIRUS STRAIN;

ANTIBODIES, NEUTRALIZING; CELL COUNT; CELL LINE; CHINA; CYTOPATHOGENIC EFFECT, VIRAL; DEAE-DEXTRAN; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; LABORATORY PROFICIENCY TESTING; NEUTRALIZATION TESTS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84867606525     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.07.011     Document Type: Article

References (35)

1. Baba M., Pauwels R., Balzarini J., Arnout J., Desmyter J., De Clercq E. Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:6132-6136.
2. Bontjer I., Melchers M., Eggink D., David K., Moore J.P., Berkhout B., Sanders R.W. Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. Journal of Biological Chemistry 2010, 285:36456-36470.
3. Chen Z., Huang Y., Zhao X., Ba L., Zhang W., Ho D.D. Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'. Journal of Acquired Immune Deficiency Syndromes 2008, 47:412-421.
4. Chong H., Hong K., Zhang C., Nie J., Song A., Kong W., Wang Y. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. Journal of Acquired Immune Deficiency Syndromes 2008, 47:535-543.
5. Fenyo E.M., Heath A., Dispinseri S., Holmes H., Lusso P., Zolla-Pazner S., Donners H., Heyndrickx L., Alcami J., Bongertz V., Jassoy C., Malnati M., Montefiori D., Moog C., Morris L., Osmanov S., Polonis V., Sattentau Q., Schuitemaker H., Sutthent R., Wrin T., Scarlatti G. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE 2009, 4:e4505.
6. Ferrantelli F., Rasmussen R.A., Buckley K.A., Li P.L., Wang T., Montefiori D.C., Katinger H., Stiegler G., Anderson D.C., McClure H.M., Ruprecht R.M. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. Journal of Infectious Diseases 2004, 189:2167-2173.
7. Huang X., Liu L., Ren L., Qiu C., Wan Y., Xu J. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses. Vaccine 2007, 25:8874-8884.
8. Huang X., Lu B., Yu W., Fang Q., Liu L., Zhuang K., Shen T., Wang H., Tian P., Zhang L., Chen Z. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS ONE 2009, 4:e4180.
9. Kent S.J., Cooper D.A., Chhi Vun M., Shao Y., Zhang L., Ganguly N., Bela B., Tamashiro H., Ditangco R., Rerks-Ngarm S., Pitisuttithum P., Van Kinh N., Bernstein A., Osmanov S. AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Medicine 2010, 7:e1000331.
10. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of Virology 2005, 79:10108-10125.
11. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T., Hunter E., Hahn B.H., Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. Journal of Virology 2006, 80:11776-11790.
12. Li Y., O'Dell S., Walker L.M., Wu X., Guenaga J., Feng Y., Schmidt S.D., McKee K., Louder M.K., Ledgerwood J.E., Graham B.S., Haynes B.F., Burton D.R., Wyatt R.T., Mascola J.R. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. Journal of Virology 2011, 85:8954-8967.
13. Lusso P. HIV and the chemokine system: 10 years later. EMBO Journal 2006, 25:447-456.
14. Mann A.M., Rusert P., Berlinger L., Kuster H., Gunthard H.F., Trkola A. HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 2009, 23:1659-1667.
15. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Lu Y., Robb M.L., Katinger H., Birx D.L. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. Journal of Virology 1999, 73:4009-4018.
16. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Medicine 2000, 6:207-210.
17. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., O'Dell S., Patel N., Shahzad-Ul-Hussan S., Yang Y., Zhang B., Zhou T., Zhu J., Boyington J.C., Chuang G.Y., Diwanji D., Georgiev I., Do Kwon Y., Lee D., Louder M.K., Moquin S., Schmidt S.D., Yang Z.Y., Bonsignori M., Crump J.A., Kapiga S.H., Sam N.E., Haynes B.F., Burton D.R., Koff W.C., Walker L.M., Phogat S., Wyatt R., Orwenyo J., Wang L.X., Arthos J., Bewley C.A., Mascola J.R., Nabel G.J., Schief W.R., Ward A.B., Wilson I.A., Kwong P.D. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
18. Montefiori D.C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods in Molecular Biology 2009, 485:395-405.
19. Nie J., Zhang C., Liu W., Wu X., Li F., Wang S., Liang F., Song A., Wang Y. Genotypic and phenotypic characterization of HIV-1 CRF01_AE env molecular clones from infections in China. Journal of Acquired Immune Deficiency Syndromes 2010, 53:440-450.
20. Nkolola J.P., Peng H., Settembre E.C., Freeman M., Grandpre L.E., Devoy C., Lynch D.M., La Porte A., Simmons N.L., Bradley R., Montefiori D.C., Seaman M.S., Chen B., Barouch D.H. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. Journal of Virology 2010, 84:3270-3279.
21. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.S., Wang S.K., Stanfield R.L., Julien J.P., Ramos A., Crispin M., Depetris R., Katpally U., Marozsan A., Cupo A., Maloveste S., Liu Y., McBride R., Ito Y., Sanders R.W., Ogohara C., Paulson J.C., Feizi T., Scanlan C.N., Wong C.H., Moore J.P., Olson W.C., Ward A.B., Poignard P., Schief W.R., Burton D.R., Wilson I.A. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
22. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., Ott R.G., Anthony R.M., Zebroski H., Hurley A., Phogat A., Chakrabarti B., Li Y., Connors M., Pereyra F., Walker B.D., Wardemann H., Ho D., Wyatt R.T., Mascola J.R., Ravetch J.V., Nussenzweig M.C. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
23. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y., Pietzsch J., Fenyo D., Abadir A., Velinzon K., Hurley A., Myung S., Boulad F., Poignard P., Burton D.R., Pereyra F., Ho D.D., Walker B.D., Seaman M.S., Bjorkman P.J., Chait B.T., Nussenzweig M.C. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
24. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Medicine 1999, 5:204-210.
25. Teng T., Shao Y. Scientific approaches to AIDS prevention and control in China. Advances in Dental Research 2011, 23:10-12.
26. Todd C.A., Greene K.M., Yu X., Ozaki D.A., Gao H., Huang Y., Wang M., Li G., Brown R., Wood B., D'Souza M.P., Gilbert P., Montefiori D.C., Sarzotti-Kelsoe M. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. Journal of Immunological Methods 2012, 375:57-67.
27. Vasan S., Schlesinger S.J., Chen Z., Hurley A., Lombardo A., Than S., Adesanya P., Bunce C., Boaz M., Boyle R., Sayeed E., Clark L., Dugin D., Boente-Carrera M., Schmidt C., Fang Q., LeiBa, Huang Y., Zaharatos G.J., Gardiner D.F., Caskey M., Seamons L., Ho M., Dally L., Smith C., Cox J., Gill D., Gilmour J., Keefer M.C., Fast P., Ho D.D. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS ONE 2010, 5:e8816.
28. Vasan S., Schlesinger S.J., Huang Y., Hurley A., Lombardo A., Chen Z., Than S., Adesanya P., Bunce C., Boaz M., Boyle R., Sayeed E., Clark L., Dugin D., Schmidt C., Song Y., Seamons L., Dally L., Ho M., Smith C., Markowitz M., Cox J., Gill D.K., Gilmour J., Keefer M.C., Fast P., Ho D.D. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS ONE 2010, 5:e8617.
29. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., Mitcham J.L., Hammond P.W., Olsen O.A., Phung P., Fling S., Wong C.H., Phogat S., Wrin T., Simek M.D., Koff W.C., Wilson I.A., Burton D.R., Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
30. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
31. Wang S., Nie J., Wang Y. Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China. Virus Research 2011, 155:137-146.
32. Wang Y., Song A., Xu S., Li X., Chong H., Zhao C., Nie J., Zhang C. Impact of HIV-1 genetic diversity in China on the measurement of viral load. Journal of Medical Virology 2008, 80:1-8.
33. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrobial Agents and Chemotherapy 2002, 46:1896-1905.
34. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
35. Yu S., Feng X., Shu T., Matano T., Hasegawa M., Wang X., Ma H., Li H., Li Z., Zeng Y. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine 2008, 26:6124-6131.